NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

Symbravo is not substitutable with other formulations of meloxicam or rizatriptan. The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of ...

Credit: Axsome Therapeutics. The approval was supported by data from the phase 3 MOMENTUM and INTERCEPT trials. Symbravo is not substitutable with other oral formulations of meloxicam or rizatriptan ...

Axsome Therapeutics, Inc. has announced the presentation of data from its SYMBRAVO® (meloxicam and rizatriptan) clinical program at the upcoming 67th Annual Scientific Meeting of the American Headache ...

Credit: Axsome Therapeutics Symbravo is expected to be available in approximately 4 months. Symbravo is not substitutable with other formulations of meloxicam or rizatriptan. The Food and Drug ...

A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours 85% and 77% of patients treated with ...

Migraines are thought to happen because of chemical changes in your brain. Nerves send signals that change the levels of certain chemicals in your body, including serotonin and calcitonin gene-related ...